Lead Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. ECOG performance status 0-2
•2. Age over 18 years
•3. Diagnosed renal cancer with clear cell histology
•4. Metastatic disease
•5. Predicted life expectancy over 2 months
•6. Targeted treatment with an anti-VEGF or anti-mTOR agent as first or second line therapy
•7. Standard imaging evaluation 4 weeks prior to inclusion
•8. Planned for standard imaging within 16 weeks after start of therapy

•1. Presence of substantial comorbidities (uncontrolled heart or respiratory dysfunction, severe renal or hepatic impairment \[Cl Cr below 30ml/h OR Bb\>3X ULN\])
•2. History of a malignancy other than non-melanoma skin cancer in the previous 5 years
•3. Any other contraindication to targeted treatments.